Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2007 - Volume 32 - Issue 4 > No Apparent Alteration of F-18 FDG Biodistribution When Inje...
Clinical Nuclear Medicine:
doi: 10.1097/01.rlu.0000257273.55996.8b
Interesting Image

No Apparent Alteration of F-18 FDG Biodistribution When Injected Shortly After Insulin Glargine

Niederkohr, Ryan D. MD; Quon, Andrew MD

Collapse Box


F-18 FDG PET scans acquired after insulin administration usually show prominent skeletal and cardiac muscle FDG uptake, which may hinder accurate scan interpretation. We performed an FDG PET/CT scan on a 25-year-old diabetic woman who received the long-acting insulin analog glargine (Lantus; Sanofi-Aventis) 3 hours before FDG injection. The scan showed no significant alteration of FDG biodistribution. Insulin glargine has no pronounced peak over 24 hours and is being used more frequently to create basal insulin level in patients with type 1 and type 2 diabetes. Our findings suggest that insulin glargine may not need to be withheld prior to PET scintigraphy.

© 2007 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.